Uridoki (418A), Q1 FY Ending November 2026: Net Sales of JPY 545 Million, Operating Income of JPY 103 Million

Uridoki has announced its financial results for the first quarter of the fiscal year ending November 2026 (December 1, 2025 - February 28, 2026).

Uridoki reported net sales of JPY 545 million for the quarter. Operating income reached JPY 103 million, and ordinary income was also JPY 103 million. Profit before tax stood at JPY 103.759 million, with net income at JPY 71.729 million. Earnings per share (EPS) for the period was JPY 16.74.

Regarding profitability, Uridoki reported an operating profit margin of approximately 18.89% and a net profit margin of approximately 13.16% against net sales, which are strong levels. The return on equity (ROE) was 14.93%, and return on assets (ROA) was 9.23%, suggesting efficient capital utilization and asset management.

From a financial health perspective, Uridoki's equity ratio is 61.8%, a healthy level. Interest-bearing debt is JPY 25.79 million, which is low relative to its total assets.

In terms of market valuation, the current stock price implies a Price-to-Earnings Ratio (PER) of 54.06x, a Price-to-Book Ratio (PBR) of 8.07x, and a Price-to-Sales Ratio (PSR) of 7.12x. These valuation metrics may reflect the market's high expectations for Uridoki's future growth. Investors will likely continue to monitor how future performance aligns with these expectations.

It should be noted that year-on-year growth rates, progress against full-year forecasts, and multi-year CAGR growth trends cannot be confirmed from the provided data.

Correction (September 19, 2026): This article covers the non-consolidated results for Q1 FY Ending November 2026. Period and accounting-scope labels have been aligned with the source document.

Source: Original financial results (Japanese).

---

Correction (September 20, 2026): interest-bearing debt was corrected to the value in the original disclosure (tanshin 140120260414503321).